Department of Cardiology and Angiology, University Hospital Tübingen, Germany.
Department of Cardiology and Angiology, University Hospital Tübingen, Germany.
Interv Cardiol Clin. 2024 Oct;13(4):451-467. doi: 10.1016/j.iccl.2024.06.001. Epub 2024 Aug 8.
Antiplatelet and anticoagulant therapies are cornerstones of secondary prevention in high-risk cardiovascular patients. Whereas in former days the focus was set on effective antithrombotic effects, more recent trials and guidelines placed emphasis on a more balanced approach, thus including the bleeding risk for an individualized therapy. Type, strength, combination, and duration are important components to modify the individual bleeding risk. Novel antiplatelet and anticoagulant agents have shown promising results that might offer safer options in the future for high-risk cardiovascular patients. This review aims to give an overview about established drug target and pharmacologic approaches that are currently in the pipeline.
抗血小板和抗凝治疗是高危心血管患者二级预防的基石。虽然过去的重点是放在有效的抗血栓作用上，但最近的试验和指南更强调采用更平衡的方法，从而将出血风险纳入个体化治疗。类型、强度、联合和持续时间是改变个体出血风险的重要因素。新型抗血小板和抗凝药物已显示出有希望的结果，这可能为未来的高危心血管患者提供更安全的选择。本综述旨在概述目前处于研发阶段的已确定的药物靶点和药理方法。
